These files are large, and you'll need at least a broadband (Cable/DSL) connection to view them. The videos stream at 225Kbps.
Speaker |
Speech Title |
Length |
Link |
|---|---|---|---|
|
Zach Hall, Ph.D., President, CIRM |
10:02 | Watch now | |
| Joan Samuelson, J.D., Member, ICOC Welcome |
6:05 | Watch now | |
| Robert Klein, Chairman, ICOC Welcome |
16:52 | Watch now | |
Session I |
|||
| Rob Negrin, M.D., Stanford Hematopoietic Stem Cell Transplantation: Where We Have Been and Where We Are Going |
29:21 | Watch now | |
| Jeff Bluestone, Ph.D., University of California, San Francisco A Cure for Type I Diabetes |
32:00 | Watch now | |
| Olle Lindvall, M.D., Ph.D., University of Lund, Sweden Stem Cell Therapy for Human Brain Disease: How Can We Make It Work? |
25:23 | Watch now | |
Session II |
|||
| Edward Penhoet, Ph.D., Vice Chair, ICOC Stem Cells and Therapies: Lessons from the FDA and Industry |
2:39 | Watch now | |
| Jane Lebkowski, Ph.D., Geron Corporation Preclinical Studies to Support Clinical Testing of Stem Cell-Based Therapies |
18:06 | Watch now | |
| Alan Smith, Ph.D., Cognate Therapeutics, Inc. GMP Banking, Manufacturing and Quality Control of Stem Cells for Clinical Use |
25:38 | Watch now | |
| Donald Fink, Ph.D., FDA Developing Stem Cell-Based Therapies: Engaging the FDA |
30:56 | Watch now | |
Session III |
|||
| Fred Gage, Ph.D., The Salk Institute Stem Cells as Tools for Disease Research and Therapy |
3:33 | Watch now | |
| Rudolph Jaenisch, Ph.D., The Whitehead Institute, MIT SCNT for Understanding Disease |
26:34 | Watch now | |
| Inder Verma, Ph.D., The Salk Institute Molecular Manipulation of Embryonic Stem Cells |
24:14 | Watch now | |
| Peter Schultz, Ph.D.,The Scripps Research Institute Small Molecules and High-Throughput Screening in Embryonic Stem Cells |
21:24 | Watch now | |
Session IV |
|||
| Peter Andrews, Ph.D., University of Sheffield, UK Self-Renewal of Stem Cells |
4:22 | Watch now | |
| Haifan Lin, Ph.D., Duke University School of Medicine Understanding Stem Cell Self-Renewal: Progress and Prospect |
18:31 | Watch now | |
| Andras Nagy, Ph.D., Mount Sinai Hospital, Toronto, Canada Development of Tools for Studying hESC Self-Renewal |
23:18 | Watch now | |
| Martin Pera, Ph.D., The Monash Institute of Medical Research, Australia Development of Conditions for Defined Culture and Scale-Up |
18:15 | Watch now | |
Session V |
|||
| Nissim Benvenisty, M.D., Ph.D., Hebrew University of Jerusalem, Israel How Can We Control Differentiation of ES Cells? |
20:31 | Watch now | |
| Irving Weissman, M.D., Stanford University Current Status of in vivo Systems to Monitor Stem Cell Differentiation and Function |
39:36 | Watch Now | |
| Michael Clarke, M.D., University of Michigan Bad Stem Cell Choices in Cancer Development |
35:11 | Watch now | |
Session VI |
|||
| Ian Duncan, Ph.D., University of Wisconsin Bridging the Gap Between Bench and Bedside |
11:48 |
Watch now | |
| David Scadden, M.D., Harvard Medical School The Stem Cell Niche: A Drugable Target? |
31:39 | Watch now | |
| Jon Odorico, M.D., University of Wisconsin Hurdles to Overcome in Applying hES Cells for Treatment of Diabetes |
31:06 | Watch now | |
| Hans Keirstead, Ph.D., University of California, Irvine Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitors: A Defined Cell Population for a Defined Need |
19:45 | Watch now | |
Conclusion |
|||
| Zach Hall, Ph.D., President, CIRM Closing Remarks |
19:32 | Watch now | |